Year: 2024

OLD GREENWICH, Conn., Nov. 12, 2024 (GLOBE NEWSWIRE) — Hudson Global, Inc. (Nasdaq: HSON) (“Hudson Global” or “the Company”), a leading global total talent solutions company, announced today financial results for the third quarter ended September 30, 2024. 2024 Third Quarter SummaryRevenue of $36.9 million decreased 6.5% from the third quarter of 2023 and 8.1% in constant currency. Adjusted net revenue of $18.6 million decreased 4.0% from the third quarter of 2023 and 5.2% in constant currency. Net loss was $0.8 million, or $0.28 per diluted share, compared to net income of $0.5 million, or $0.17 per diluted share, for the third quarter of 2023. Adjusted net loss per diluted share (non-GAAP measure)* was $0.13 compared to adjusted net income per diluted share of $0.24 in the third quarter of 2023. Adjusted...

Tuesday, Schouw & Co. released its interim report for the third quarter of 2024; As expected, consolidated revenue for Q3 2024 was down on the year before, driven by a drop in volume sales combined with lower prices. EBITDA was also down compared to the very strong Q3 2023. Cash flows from operations remained at a high level. HighlightsDKK 9.5bn revenue – a reduction of 9% DKK 834m EBITDA – a decrease of 8% DKK 1.2bn cash flows from operations – a reduction of DKK 0.3bn DKK 14.6 earnings per share – a decrease of 14% 13.3% ROIC excluding goodwill – an increase of 0.9 ppStatement by Jens Bjerg Sørensen, President of Schouw & Co. – Overall, Q3 2024 was a good quarter for Schouw & Co. with solid profitability and continued strong cash flow generation. Our portfolio companies operate in volatile and uncertain environments...

Conference call will be held today, Tuesday, November 12 at 9:00 am ET CARMEL, Ind., Nov. 12, 2024 (GLOBE NEWSWIRE) — NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies for chronic and debilitating conditions in children and adults, today announced results for the third quarter period ended September 30, 2024. 3Q24 Financial HighlightsRevenues increased 40% to $667 thousand in the three months ended September 30, 2024 (the “3Q24”) compared to $477 thousand in the three months ended September 30, 2023 (the “3Q23”). Operating loss improved by 45% compared to the 3Q2023.Recent Operational HighlightsExpanded total covered lives to approximately 35 million compared to 4.5 million as of October 1, 2023. Recent medical policy coverages include:BCBS...

VANCOUVER, British Columbia, Nov. 12, 2024 (GLOBE NEWSWIRE) — Standard Lithium Ltd. (“Standard Lithium” or the “Company”) (TSXV:SLI) (NYSE American:SLI) (FRA:S5L), a leading near-commercial lithium company, today announced its financial and operating results for the fiscal first quarter 2025 ended September 30, 2024. “Our fiscal first quarter highlights demonstrate our commitment to doing what we say we’re going to do,” said David Park, Chief Executive Officer and Director of Standard Lithium. “We told you that we would pursue Government grants, and we have been conditionally approved for $225 million – one of the largest grant awards for a domestic critical minerals project – from the U.S. Department of Energy. The conditional grant is a testament to the world-class caliber of the South West Arkansas project and the good work...

THIS NEWS RELEASE IS NOT FOR DISTRIBUTION IN THE UNITED STATES OR TO U.S. NEWS AGENCIES HONG KONG, Nov. 12, 2024 (GLOBE NEWSWIRE) — Century Global Commodities Corporation (“Century” or the “Company”) (TSX: CNT) is pleased to announce that it has filed its condensed consolidated interim financial statements for the second fiscal quarter ended September 30, 2024 and the related management discussion and analysis (“MD&A”). Copies of these documents are available under Century’s SEDAR+ profile at http://www.sedarplus.ca and will also be posted on Century’s website at www.centuryglobal.ca. As of September 30, 2024, the Company had net working capital* of $5.7 million, consisting of unrestricted free cash, bank deposits and marketable securities totaling $4.2 million, together with accounts receivables, inventories and other current...

Second consecutive quarter of 20 ReWalk systems sold Robust growth in U.S. ReWalk pipeline of approximately 70 qualified leads for potential claim submission with Medicare and other U.S. payorsMARLBOROUGH, Mass. and YOKNEAM ILLIT, Israel, Nov. 12, 2024 (GLOBE NEWSWIRE) — Lifeward Ltd., (Nasdaq: LFWD) (“Lifeward” or the “Company”), a global market leader delivering life-changing solutions in physical rehabilitation and recovery, today announced its financial results for the three months and nine months ended September 30, 2024. Recent Highlights and Milestones for LifewardLifeward initiated actions to further streamline its U.S. operations including closing two U.S. facilities to complete the integration of AlterG. The actions are expected to save the Company approximately $3 million in operating expenses and improve gross margins...

Fully enrolled the Phase 2/3 trial of lead asset CTX-009 (DLL4 and VEGF-A bispecific antibody) in patients with biliary tract cancers (BTC); top-line data readout is on track for the end of the first quarter of 2025. Designing a Phase 2 trial of CTX-009 in combination with chemotherapy in patients with DLL4-positive colorectal cancer (CRC) treated in the second-line setting; trial initiation expected in mid-2025. Identified neural cell adhesion molecule (NCAM or CD56) as a potential biomarker of response to CTX-471 based on data from the Phase 1 trial; planning a Phase 2 trial in patients with tumors expressing NCAM for mid-2025. Fully enrolled the second dosing cohort of the Phase 1 dose-escalation study of CTX-8371 (PD-1 x PD-L1 bispecific antibody); enrollment into the third dosing cohort is expected to begin in the coming month. Cash...

On track to report interim data in six-month evaluable patients in ADVANCED-2 trial of TARA-002 in NMIBC in 4Q 2024 Expect to report interim 12-month data in ADVANCED-2 trial of TARA-002 in NMIBC in mid-2025 In pediatric LMs patients, TARA-002 demonstrated encouraging results and was generally well-tolerated in the first cohort of Phase 2 STARBORN-1 trial; initial results from next cohort expected in 1H 2025 Received Fast Track designation from the U.S. FDA for IV Choline Chloride; expect to dose first patient in THRIVE-3 registrational trial in 1Q 2025NEW YORK, Nov. 12, 2024 (GLOBE NEWSWIRE) — Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today provided a business update and announced financial results for the third quarter...

SOLANA BEACH, Calif., Nov. 12, 2024 (GLOBE NEWSWIRE) — Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, dermatologic and neurological conditions, today reported its financial and operating results for the three months ended September 30, 2024, and provided a business update. “With the ongoing, rapid progress of our pipeline, we anticipate multiple clinical readouts over the next 15 months,” stated Gregory D. Gorgas, President and CEO of Artelo Biosciences. “Starting with ART26.12, our promising Fatty Acid Binding Protein 5 (FABP5) inhibitor drug candidate, we received FDA clearance to begin trials in chemotherapy-induced peripheral neuropathy. This debilitating condition, for which there is no...

Golden Matrix Group Inc,The Q3 results reflect the Company’s robust growth strategy and expansion efforts across key markets.Year-to-Date Revenue up 55% to $105.3 Million Company’s Classics for a Cause Acquisition Successfully Integrated LAS VEGAS, Nov. 12, 2024 (GLOBE NEWSWIRE) — Golden Matrix Group Inc. (NASDAQ: GMGI) (“Golden Matrix” or the “Company”), a global developer, licensor, and operator of online gaming platforms, today announced strong financial and operational results for the third quarter ended September 30, 2024. The results reflect the Company’s robust growth strategy and expansion efforts across key markets, including the successful acquisition and integration of Classics for a Cause. Brian Goodman, CEO of Golden Matrix, commented, “Golden Matrix’s Q3 performance demonstrates our commitment and success...